519 related articles for article (PubMed ID: 12682003)
21. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
[TBL] [Abstract][Full Text] [Related]
22. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
[TBL] [Abstract][Full Text] [Related]
23. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
[TBL] [Abstract][Full Text] [Related]
24. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Ulm K; Berger PB; Schömig A
Circulation; 2006 Nov; 114(19):2040-6. PubMed ID: 17060377
[TBL] [Abstract][Full Text] [Related]
25. ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design.
Capodanno D; Prati F; Pawlowsky T; Ramazzotti V; Albertucci J; La Manna A; Robert G; Tamburino C
J Cardiovasc Med (Hagerstown); 2010 Feb; 11(2):130-6. PubMed ID: 19829141
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
[TBL] [Abstract][Full Text] [Related]
27. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.
Dominguez-Rodriguez A; Abreu-Gonzalez P; Avanzas P; Bosa-Ojeda F; Samimi-Fard S; Marrero-Rodriguez F; Kaski JC
Atherosclerosis; 2009 Oct; 206(2):523-7. PubMed ID: 19380134
[TBL] [Abstract][Full Text] [Related]
28. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H
Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
[TBL] [Abstract][Full Text] [Related]
29. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shimada YJ; Nakra NC; Fox JT; Kanei Y
Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
[TBL] [Abstract][Full Text] [Related]
31. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
32. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Roy L; Déry JP; Courtis J; Nault I; Poirier P; Costerousse O; De Larochellière R
Am Heart J; 2008 Jul; 156(1):135-40. PubMed ID: 18585508
[TBL] [Abstract][Full Text] [Related]
33. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Piccolo R; Eitel I; Galasso G; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
Vascul Pharmacol; 2015 Oct; 73():32-7. PubMed ID: 26071862
[TBL] [Abstract][Full Text] [Related]
34. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
35. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
36. Dissolution of thrombus formed during direct coronary angioplasty with a single 10 mg intracoronary bolus dose of abciximab.
Thuraisingham S; Tan KH
Int J Clin Pract; 1999 Dec; 53(8):604-7. PubMed ID: 10692754
[TBL] [Abstract][Full Text] [Related]
37. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
[TBL] [Abstract][Full Text] [Related]
38. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
[TBL] [Abstract][Full Text] [Related]
39. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
[TBL] [Abstract][Full Text] [Related]
40. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study.
Tousek P; Rokyta R; Tesarova J; Pudil R; Belohlavek J; Stasek J; Rohac F; Widimsky P
Acute Card Care; 2011 Sep; 13(3):116-22. PubMed ID: 21526919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
